Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says

By Emilie Ruscoe · March 9, 2026, 6:40 PM EDT

Brass of Ultragenyx Pharmaceutical Inc. are facing shareholder derivative claims they caused the company to overstate prospects for a drug to treat a bone disease, hurting investors and opening the company...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Simutis v. Kakkis et al

Case Number

Court

California Northern

Nature of Suit

Stockholders Suits

Date Filed

March 06, 2026

Recent Articles By Emilie

January 29, 2026
Inspire Medical Leaders Face Suit Over Apnea Device Rollout
January 21, 2026
Health Tech SPAC Execs Ink $10M Investor Settlement
November 10, 2025
IRhythm Denied Early Win On Investor Scienter & Loss Claims
November 04, 2025
IRhythm Investors Seek Class Cert. In Heart Device Suit
November 03, 2025
Biotech Co. Agrees To Reforms After Co-Founder's Conviction
October 28, 2025
Ex-Philips CEO Can't Undo Finding He Misled Shareholders
October 27, 2025
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud
October 17, 2025
Sana Biotech Fights Investor Fraud Claims Over Trial Data
October 09, 2025
Tivity Health Investors Seek Final OK Of $17M Settlement
October 06, 2025
2 Firms To Lead Humana Investor Suit Over Post-COVID Costs